- PharmAust (PAA) has revealed preliminary results show its drugs are effective in inhibiting COVID-19 in human lung cells
- Researchers in Melbourne have been testing the effect monepantel (MPL) and monepantel sulfone (MPLS) has on the deadly virus
- This recent testing found MPL and MPLS inhibited COVID-19 in human lung cells by up to 95 per cent
- PharmAust said following these initial results, further testing will now undertaken to better understand the drug’s effect
- PharmAust’s Chief Scientific Officer, Richard Mollard, also said the was very pleased with these latest results
- Shares in PAA are trading 4.26 per cent in the green at 24.5 cents each
PharmAust: Continues testing COVID-19 treatment
